雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Bone and Calcium Abnormalities in Malignancy. Anti-FGF23 antibody therapy for patients with tumor-induced osteomalacia. Kinoshita Yuka 1 , Fukumoto Seiji 2 1Division of Nephrology & Endocrinology, Department of Medicine, The University of Tokyo Hospital, Japan. 2Division of Nephrology & Endocrinology, Department of Medicine, The University of Tokyo Hospital, Japan. pp.1217-1222
Published Date 2014/7/28
DOI https://doi.org/10.20837/4201408093
  • Abstract
  • Look Inside
  • Reference

 Tumor-induced osteomalacia(TIO)is a disease caused by fibroblast growth factor 23(FGF23)secreted from the causative tumor. This disease is cured by complete surgical removal of the tumor. However, there are several difficult cases in which the responsible tumors cannot be found, are incompletely removed, or relapse after the surgery. Anti-FGF23 antibody is being studied as a novel therapy for FGF23-related hypophosphatemic diseases. The efficacy of anti-FGF23 antibodies were confirmed using a murine model of X-linked hypophosphatemic rickets(XLHR),which is the most common heritable form of FGF23-related hypophosphatemic disease. In addition, results of phase I study of single injection of humanized anti-FGF23 antibody for adult patients with XLHR were recently published and the safety and effectiveness of this antibody was shown. This antibody therapy may be useful for patients with TIO with similar pathogenesis to that of XLHR.



基本情報

電子版ISSN 印刷版ISSN 0917-5857 医薬ジャーナル社

関連文献

もっと見る

文献を共有